Moderna Shares Pull Back Monday After Record Rally Profit-Taking

Moderna Inc. shares traded lower Monday morning, consolidating after a multi-day rally driven by clinical trial success.

Moderna shares were trading near recent highs. What's next for MRNA stock?

Phase 3 Trial Success Validates mRNA Oncology Platform

The major catalyst came last week when Moderna and development partner Merck & Co. announced positive topline results from their Phase 3 INTerpath-001 trial. The study evaluated intismeran autogene in combination with Merck's Keytruda in patients with high-risk stage IIB-IV melanoma.

The trial met its primary endpoint of recurrence-free survival and the key secondary endpoint of distant metastasis-free survival, demonstrating that the combination therapy significantly extended the time patients lived without cancer recurrence compared to Keytruda alone.

The successful data readout represents the first positive Phase 3 trial result for a personalized mRNA cancer vaccine, providing landmark proof-of-concept for Moderna's platform beyond COVID-19 and respiratory treatments.

Following Wednesday's announcement, Moderna shares surged more than 120% in a single trading session, triggering a wave of analyst upgrades on Wall Street and adding tens of billions of dollars in market capitalization.

MRNA Shares Pull Back Monday Morning

MRNA price action: As of Monday's data release, Moderna shares were down 6.49% at $135.71.